VDR and neoplasm: In particular, the MRD status appears to be influenced by the genetic variation of genes involved in pharmacokinetics/pharmacodynamics of anti-leukemic drugs (RFC and potentially VDR, acting as pleiotropic transcriptional regulator) as well as the genes involved in anti-tumor immunity of the host (IL15 and potentially VDR).